Designing Optimal Bioassays for Measuring ADCC & ADCP Activity

Over the last decades, the interest in therapeutic monoclonal antibody (mAb) development has led to a need for sensitive, reliable, and biologically relevant bioassays for measuring Fc-effector activity.

Traditional methods closely resemble what happens in the body but are labor-intensive and have a high level of inherent variability due to the use of primary human cells from different donors.  Conversely, reporter-gene-based approaches can overcome some of these drawbacks by allowing highly accurate determination of the ability of mAbs to elicit ADCC or ADCP but represent a more artificial environment.

Consequently, a significant challenge in designing reporter-gene assays is to make them as physiologically relevant as possible. 

Download the white paper to learn about Fc-effector activity bioassay design and how the iLite^® assays have been designed to offer a powerful and convenient way of measuring ADCC and ADCP activity while minimizing the disadvantages usually associated with reporter-gene assays.